Regulatory PathRegulatory requirements compared

Active substance

Brexucabtagene autoleucel

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
Tecartus1 * 10^6 + 1 * 10^8 cellsCell suspension for infusion · Intravenous use1 BagSAR 1694937.75Biological · PrescriptionGilead Sciences Ireland UCValid
Tecartus2 * 10^6 + 2 * 10^8 cellsCell suspension for infusion · Intravenous use1 BagSAR 1694937.75Biological · PrescriptionGilead Sciences Ireland UCValid
Indications — CHI Daman Drug Formulary

MANTLE CELL LYMPHOMA

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
TECARTUS02516667200000000 CELLS / BAGSUSPENSION · INTRAVENOUSGILEAD SCIENCES CANADA INC
TECARTUS02532719100000000 CELLS / BAGSUSPENSION · INTRAVENOUSGILEAD SCIENCES CANADA INC

Safety signals and safety-related labeling changes

All safety entries for brexucabtagene autoleucel →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.